Printer Friendly

Aspirin's chemopreventive effects seen 10 years after Tx initiation.

Taking 300 mg of aspirin daily for at least 5 years was shown to prevent colorectal cancer in an analysis of two large randomized trials. The effect was seen beginning 10 years after treatment was initiated.

Although this strategy might be effective in certain high-risk groups, further research is needed to elucidate the risks and benefits of aspirin chemoprevention in various clinical settings, the researchers wrote. The effectiveness of colonoscopy screening and the risk of bleeding complications with long-term aspirin use also should be considered, they noted.

Dr. Andrew Chan of the gastrointestinal unit at Massachusetts General Hospital, Boston, agreed in an accompanying commentary. "These findings are not sufficient to warrant a recommendation for the general population to use aspirin for cancer prevention," he wrote (Lancet 2007;369:1577-8).

Previous observational studies had reported a decreased incidence of colorectal cancers in regular users of aspirin, but two large trials did not demonstrate a decreased risk over 10 years of follow-up. Longer follow-up is needed, given that the delay is 10-15 years between initiation of development of an adenoma and colorectal cancer, wrote Dr. Peter Rothwell, professor of clinical neurology at the University of Oxford (England), and associates (Lancet 2007;369:1603-13).

Their analysis focused on the British Doctors Aspirin Trial and the UK Transient Ischaemic Attack Aspirin Trial; there was a median follow-up of 23 years in both trials.

During that follow-up period, subjects who took at least 300 mg of aspirin a day for at least 5 years were significantly less likely to develop colorectal cancer than were controls (hazard ratio [HR] 0.63), according to a pooled analysis of the two trials. The researchers found no significant effect on any other type of cancer.

The preventive effect was strongest in years 10-19, when the HR for aspirin users was 0.60, but a significantly reduced HR of 0.74 was seen in years 20 and later for the subjects who took aspirin. No significant preventive effect was seen at 0-9 years (HR 0.92).

The British Doctors Aspirin Trial randomized doctors in 1978 and 1979 into a group of 3,429 taking a daily dose of 500 mg of aspirin and a control group of 1,710 who took nothing. Treatment continued for 5-6 years.

The UK Transient Ischaemic Attack Aspirin Trial randomized 2,449 patients over age 40 who had already had a transient ischemic attack or mild ischemic stroke to receive daily doses of either 1,200 mg or 300 mg of aspirin, or placebo. Recruitment took place between 1979 and 1985, with the trial ending in 1986. The researchers performed a subgroup analysis of only those patients who took aspirin for at least 5 years.

The researchers identified trial participants who had developed cancer through cancer registries and death certificates.


London Bureau
COPYRIGHT 2007 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Gastroenterology
Author:Gardner, Jonathan
Publication:Internal Medicine News
Geographic Code:1USA
Date:Jul 1, 2007
Previous Article:Pillcam shows promise for colorectal screening.
Next Article:Aspirin may reduce risk of certain colorectal cancers.

Related Articles
Aspirin costs more than Colonoscopy for Colorectal Cancer prevention. (Hypothetical Cohort of 100,000).
NSAIDs, aspirin show protective effect against colorectal cancer. (Benefits Accrue After 2 Years).
Aspirin and adenomas.
Aspirin used incorrectly for cardioprotection.
5-aminosalicylate recommended for preventing colon cancer in UC.
Daily aspirin and cancer.
Aspirin may reduce risk of certain colorectal cancers.
Aspirin may prevent cancer in Lynch syndrome.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters